CA
CARM

Cliff Asness’s Carisma Therapeutics CARM Stock Holding History

Cliff Asness’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,096
Closed -$164K – 2208
2022
Q2 		$164K Buy
10,096
+8,431
+506% +$96.5K ﹤0.01% 2017
2022
Q1 		$20K Sell
1,665
-7,857
-83% -$110K ﹤0.01% 2204
2021
Q4 		$155K Buy
+9,522
New +$192K ﹤0.01% 2119

Other funds holding CARM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $9.93B AUM 28.91% 1-Year Est. Return

Cliff Asness's CARM Position: Q3 2022 in Review

Cliff Asness sold out of Carisma Therapeutics (CARM) in Q3 2022, closing a stake of 10,096 shares — an estimated $164K sold.

Cliff Asness first reported a position in CARM in Q4 2021 and held it in 3 quarters. The position peaked at $164K in Q2 2022. 68 funds tracked by Wall St. Rank hold CARM as of Q3 2022.

  • Cliff Asness reported no remaining Carisma Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cliff Asness sold 10,096 Carisma Therapeutics shares in Q3 2022, an estimated $164K.
  • Cliff Asness first reported a position in Carisma Therapeutics in Q4 2021 and held it in 3 quarters.
  • Cliff Asness's Carisma Therapeutics position peaked at $164K in Q2 2022.
  • 68 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q3 2022.

Based on AQR Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.